920 Cytosolic HMGB1 expression in human renal clear cell cancer indicates higher pathological T stages and tumor grades

Takeuchi, Tokio; Sakazume, Koichi; Tonooka, Akiko; Zaitsu, Masayoshi; Mikami, Koji; Uekusa, Toshimasa

doi:10.1016/s1569-9056(12)60917-8

Cited by 11 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nuclear HMGB1 binds to DNA and interacts with various transcription factors, including NF-jB, p53, and TATA-binding proteins [26][27][28]. Cytoplasmic HMGB1 was found to bind to a number of molecules related to cancer progression via promoting cell cycle progression, cell proliferation, and antiapoptosis [29,30]. Extracellular HMGB1 binds to several receptors, including the receptor for advanced glycation end products (RAGE), Toll-like receptor (TLR)-2, TLR-4, TLR-9, activating Ras-MAP kinase (MAPK) and the NF-jB/ MAPK pathway [31,32].…”

Section: Introductionmentioning

confidence: 99%

Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy

et al. 2017

View full text Add to dashboard Cite

Background Biomarkers predicting the response to the anticancer treatment and prognosis in patients with advanced hepatocellular carcinoma (HCC) are required. Recently, high mobility group box 1 (HMGB1) was reported to promote HCC progression and be associated with poor prognosis for patients with HCC. The purpose of this study was to assess serum HMGB1 concentrations before and during sorafenib treatment or hepatic arterial infusion chemotherapy (HAIC) and to explore the ability of serum HMGB1 concentrations to predict prognosis. Methods Serum HMGB1 concentrations were measured in 71 and 72 patients with advanced HCC treated with sorafenib and HAIC, respectively, to assess their usefulness for prediction of the response to the treatment and prognosis. Results Multivariate analysis identified high HMGB1 at 4 weeks (P = 0.001), high a-fetoprotein (AFP) at baseline (P = 0.025), tumor liver occupying rate (P = 0.009) and modified RECIST (mRECIST, P \ 0.0001) as independent Kazuhiko Masuda and Atsushi Ono are the co-first authors.The original version of this article was revised: An article note about co-first authorship was added and the second sentence in the subheading ''Results'' under the ''Abstract'' section was corrected. predictors of poor overall survival in sorafenib treatment. High HMGB1 at 4 weeks (P = 0.025), vascular invasion to the hepatic vein (Vv) (P = 0.009), mRECIST (P \ 0.0001) and Child-Pugh B (P = 0.004) were identified as independent predictors of poor overall survival in HAIC treatment. The concentrations of HMGB1 at baseline and 4 weeks were not correlated with conventional tumor markers and progressive disease assessed by mRECIST at 8 weeks.Conclusions These results suggest that serum HMGB1 at 4 weeks after the start of treatment might be a useful biomarker with added value to the conventional tumor marker and radiologic responses to predict poor overall survival in patients with advanced HCC treated with sorafenib or HAIC.

show abstract

Section: Introductionmentioning

confidence: 99%

Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Regions of gains detected in more than 50% of the cases were located at 5q21.2, 5q3, and 14q32. 33 the presence of metachronous metastasis was correlated with subgroup 2 ( Figure 3A). However, no correlation of each subgroup with overall survival could be found.…”

Section: Differences In the Scna Patterns Between Subgroups 1 Andmentioning

confidence: 86%

“…Second, HMGB1 is abundantly expressed in almost all human cells, and plays an important role as a chromatin‐associated nuclear protein 31 . Overexpression of HMGB1 occurs in a variety of human cancers, such as prostate cancer, 32 RCC, 33 hepatocellular carcinoma, 34 lung cancer, 35 colorectal cancer, 36 and gastric cancer, 37 which may suggest a potential oncogenic role of HMGB1 . This finding may mean that low expression of HMGB1 is correlated with good prognosis in various cancers.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of somatic copy number alterations in clear cell renal cell carcinoma

Tsuyukubo

Ishida

Osakabe

et al. 2020

Molecular Carcinogenesis

View full text Add to dashboard Cite

Somatic copy number alterations (SCNAs) are important biological characteristics that can identify genome‐wide alterations in renal cell carcinoma (RCC). Recent studies have shown that SCNAs have potential value for determining the prognosis of RCC. We examined SCNAs using the Affymetrix platform to analyze samples from 59 patients with clear cell RCCs (ccRCCs) including first cohort (30 cases) and second cohort (validation cohort, 29 cases). We stratified SCNAs in the ccRCCs using a hierarchical cluster analysis based on SCNA types, including gain, loss of heterozygosity (LOH), copy neutral LOH, mosaic, and mixed types. In this way, the examined two cohorts were categorized into two subgroups (1 and 2). Although the frequency of mixed type was higher in subgroup 1 than in subgroup 2 in the two cohorts, the association did not reach statistical significance. There was a significant difference in the frequency of metachronous metastasis between subgroups 1 and 2 (subgroup 2 > 1). In addition, subgroup 2 was retained in multivariate analysis of both cohorts. We examined whether there were specific alleles differing between subgroups 1 and 2 in both cohorts. We found that there was indeed a statistically significant difference in the 3p mixed types. Among the 3p mixed type, we found that 3p24.3 mixed type was inversely correlated with the presence of metachronous metastasis in ccRCC. The association was also retained in multivariate analysis in second cohort. We suggest that the 3p24.3 mixed type may be a novel marker to predict a favorable prognosis in ccRCC.

show abstract

“…Recently, we have examined immunohistological expressions of HMGB1 and HMGB2 in surgically resected human clear cell renal cancer specimens [15]. There, HMGB1 was expressed in the nucleus in 93.9% of clear cell renal cancers, while its expression in the cytosol was noted in 48.5%.…”

Section: Introductionmentioning

confidence: 99%

HMGB1 and HMGB2 Expression Patterns in Human Papillary Renal Cancers

Takeuchi¹,

Sakazume²,

Tonooka³

et al. 2013

OJU

View full text Add to dashboard Cite

High mobility group box (HMGB) proteins are nuclear nonhistone chromosomal proteins that bend DNA, bind preferentially to distorted DNA structures, and promote the assembly of site-specific DNA binding proteins. Recent reports indicate that HMGB1 has a dual function, a cytokine in addition to a nuclear protein. The increased expression of HMGB1 has been reported for several different tumors. Here, we assessed HMGB1 and HMGB2 expressions in two cases of papillary renal cell carcinoma. One case with pT1a, Grade 2 showed HMGB1 expression in the nucleus and cytosol and HMGB2 expression in the nucleus, but not in the cytosol. In the other case, there were three renal tumors, one of which was clear cell renal cell carcinoma with pT1a, Grade 3 and two were papillary renal cell carcinomas, Grade 2 (5 mm and 2 mm in the diameter). Both HMGB1 and HMGB2 were expressed in the nucleus and cytosol of papillary carcinoma. In the clear cell carcinoma of this case, HMGB1 expression was stained both in the nucleus and cytosol, while HMGB2 was observed in the nucleus, but not in the cytosol. More samples need to be further investigated in order to draw conclusions concerning HMGB expressions in papillary renal cell carcinomas.

show abstract

920 Cytosolic HMGB1 expression in human renal clear cell cancer indicates higher pathological T stages and tumor grades

Cited by 11 publications

References 0 publications

Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy

Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy

Comprehensive analysis of somatic copy number alterations in clear cell renal cell carcinoma

HMGB1 and HMGB2 Expression Patterns in Human Papillary Renal Cancers

Contact Info

Product

Resources

About